Six months after receiving infusions of their own T cells—genetically engineered ex vivo to carry chimeric antigen receptors (CAR) that bind to proteins on the
For more than half a century, the treatment of cancer has relied heavily on radiation, surgery, chemotherapy and, increasingly, the use of drugs that target
Amyloid-β proteins form plaques in the brain that are a hallmark of Alzheimer’s disease. Designed to clear these plaques, the antibody aducanumab is demonstrating early
Oncologist You Lu of Sichuan University’s West China Hospital in Chengdu and colleagues will soon begin trialing a new CRISPR-based immunotherapy in 10 patients with
Following the deaths of three patients in a phase II cancer immunotherapy clinical trial, Juno Therapeutics has put the brakes on the study. The firm
Removing built-up plaques of amyloid-β in the brain is a long-sought therapy for patients with Alzheimer’s disease, but for a variety of reasons, few treatments
Precision medicine is all about the two T’s—targets and treatments—targets that emerge from analyses of patient-specific information, and treatments that hit these targets. Both T’s,
In late 2011, the outlook for AstraZeneca’s cancer drug Lynparza (olaparib) was grim. After an interim analysis revealed disappointing results in a Phase 2 trial,
A set of 11 genes may be key to distinguishing patients with sepsis, systemic inflammation caused by infection, from patients suffering from inflammation caused by
Scientists in Korea have injected human embryonic stem cell (hESC)-derived retinal support cells into the eyes of four men with macular degeneration, according to a
Patients with Leber’s congenital amaurosis (LCA), a genetic blindness disorder caused by a mutation in the retinal pigment epithelium 65 (RPE65) gene that encodes a
Created by ePubSystems. Contact Us for similar site for your university or institute.